Results 211 to 220 of about 17,128 (260)

Differential Cancer Risks and Noninvasive Predictors in MASLD, MetALD, and ALD: A Longitudinal Analysis. [PDF]

Gut Liver
Park H, Lee JY, Koo JE, Lee JS, Park S, Park HW, Chang HS, Kim HK, Choe J, Shim JH.   +9 more
europepmc   +1 more source

Lipid Metabolic Reprogramming and Bioactive Lipid Signaling in MASLD: Molecular Mechanisms, Pathogenesis and Therapeutic Opportunities. [PDF]

Int J Mol Sci
Ábel T, Csobod Csajbókné É.
europepmc   +1 more source

Commentary on: Genetic predictors of GLP1 receptor agonist weight loss and side effects (Nature volume 653, pages 770–775 (2026))

Journal of Diabetes Investigation, EarlyView.
Gotaro Toda, Toshimasa Yamauchi
wiley   +1 more source

A pitfall in the evaluation of Sampson‐estimated small dense LDL cholesterol in metabolic disorders: Is it equivalent to directly measured sdLDL‐C?

Journal of Diabetes Investigation, EarlyView.
Tsutomu Hirano
wiley   +1 more source

MASLD a rak wątrobowokomórkowy

Wasilewicz, Michał P., Kukla, Michał
openaire   +1 more source

Lipidomics in MASLD and MetALD

Govalan, Rajalakshmi, Chen, Vincent L.
openaire   +1 more source

Hyperhomocysteinemia is linked to MASLD

European Journal of Internal Medicine
Homocysteine (Hcy) levels are elevated in different conditions, including cardiovascular diseases (CVD), diabetes, and metabolic-associated steatotic liver disease (MASLD). In this observational retrospective study, we analyzed Hcy levels in a population of 901 outpatients, considering its putative etiological role in MASLD.A total of 901 outpatients ...
Giusi Graziano, Antonio Moschetta, E Berardi   +2 more
exaly   +4 more sources

Some of the next articles are maybe not open access.

Related searches:

The pathophysiology of MASLD: an immunometabolic perspective

Expert Review of Clinical Immunology, 2023
Metabolic-associated liver diseases have emerged pandemically across the globe and are clinically related to metabolic disorders such as obesity and type 2 diabetes. The new nomenclature and definition (i.e. metabolic dysfunction-associated steatotic liver disease - MASLD; metabolic dysfunction-associated steatohepatitis - MASH) reflect the nature of ...
Julian, Schwärzler, Felix, Grabherr, Christoph, Grander, Timon E, Adolph, Herbert, Tilg   +4 more
openaire   +2 more sources

Roles of immune dysregulation in MASLD

Biomedicine and Pharmacotherapy
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease worldwide. Its occurrence and progression involve the process from simple hepatic steatosis to metabolic dysfunction associated steatohepatitis (MASH), which could develop into advanced liver fibrosis, cirrhosis, or hepatocellular carcinoma (HCC ...
Huabing Zhang, Jiajin Li, Kechao Tang
exaly   +3 more sources

MASLD: a disease in flux

Nature Reviews Gastroenterology & Hepatology
To coincide with the 20th anniversary of Nature Reviews Gastroenterology & Hepatology, we asked three experts to reflect on the past, present and future of metabolic dysfunction-associated steatotic liver disease (MASLD) research and clinical management.
Alina M. Allen, Juan Pablo Arab, Vincent Wai-Sun Wong   +2 more
openaire   +3 more sources